Research Reports

Report No. 005 Effects of dietary collagen peptides
Report No. Effects of dietary collagen peptides
005

Overview

It is necessary to conduct clinical trials to elucidate the effectiveness of dietary collagen peptides (CP) on health conditions. This report will show the following three from our clinical trials.
(1) The clinical trial on the skin conditions.
(2) The clinical trial on skin damage by UV rays.
(3) The clinical trial on immune function*1.
These results are published in peer-reviewed papers.

*1: This is the first clinical trial to demonstrate the effect of CP on immune function.

(1)The effect of CP on the skin conditions.

Many women likely expect the benefits of dietary CP to improve skin conditions. With aging, skin wrinkles increase, and skin smoothness is lost. Then, it is interesting whether the intake of CP alleviates these age-related changes. To elucidate the effects, we conducted a double-blind, placebo-controlled clinical trial on Japanese females aged 35 to 65 (with half of the population aged 50 or older and the other half aged younger than 50 years) (Reference 1).
In this trial, subjects consumed either 5 g of CP-free food (called a placebo, in this case, dextrin) or CP (manufactured by Nippi) dissolved in water or hot water every day after dinner for 8 weeks. The skin properties were evaluated with the image analysis of the VISIA before (0 weeks) and after 4 and 8 weeks of the intervention. The VISIA takes pre- and post-intervention facial photography in the same manner to evaluate wrinkles, unevenness/coloration, redness, pores, and spots reproducibly by processing facial image information. In addition, a questionnaire on the skin condition was conducted at 4 and 8 weeks. The question was "How do you feel about your skin condition compared to before the intake?". Subjects answered 1: worse, 2: same, and 3: better. We confirmed that this questionnaire was an effective means of assessing skin conditions in the trial in 2009 (Reference 2).
The data before the intervention showed that the wrinkle number increased with aging (Figure 1). Figure 2 shows an example of an image of facial skin and the wrinkles determined by VISIA (green lines). Figure 3 shows that the decrease in the wrinkle number was more pronounced in the CP group than in the placebo group, and the difference was statistically significant at 8 weeks (subgroup analysis: age < 60 years). The decrement in the CP group at 8 weeks was equivalent to a rejuvenation effect of 3.7 years based on the regression equation in Figure 1. The decrease in the number of unevenness/coloration was significantly more pronounced in the CP group than in the placebo group at 8 weeks (subgroup analysis: dry skin; Figure 4). Moreover, the decrease in the number of red areas (indicators of acne scars and inflammation) tended to be significantly more pronounced in the CP group than in the placebo group at 8 weeks (subgroup analysis for dry skin; Figure 5). In the questionnaire survey comparing skin conditions before and after intake, the CP group showed significant improvement compared to the placebo group at 8 weeks, and this improvement was more pronounced in subjects under 50 years of age (Figure 6).
These results indicate that dietary CP improved facial skin properties of wrinkles, unevenness/coloration, and redness, making the skin look more even and beautiful. These benefits accompanied the subjective feeling of ameliorating the skin condition, which is the advantage of dietary CP and probably expands the collagen peptide market.


Figure 1. Increase in the wrinkle number with aging.
The data before the intervention shows that the wrinkle number increased with aging, with a regression line of y=0.561x-13.049 and a coefficient of determination of R²=0.227.


Figure 2. Changes in wrinkles in the CP group.
The original image is on the right, and the green line on the left shows the wrinkles determined by VISIA. Compared to the pre-treatment (0 weeks), wrinkles were less noticeable at 4 and 8 weeks (an example of the CP group).

Figure 3. Change in the wrinkle number.
The decrease in the wrinkles number was more pronounced in the CP group than in the placebo group at 4 weeks, and the difference was significant at 8 weeks. This difference corresponds to a rejuvenation effect of 3.7 years calculated based on the regression line in Figure 1. Subgroup analysis for ages of 35-59 years. Mean ± SD.*; P < 0.05. n is the number of subjects.


Figure 4. Change in the unevenness/coloration number.
The decrease in the unevenness/coloration number was more pronounced in the CP group compared to the placebo group at 4 weeks, and the difference was significant at 8 weeks. Subgroup analysis for subjects with dry skin. Mean ± SD.*; P < 0.05. n is the number of subjects.


Figure 5. Change in the red areas number.
After 8 weeks, the change in the number of red areas tended to be significantly more pronounced in the CP group compared to the placebo group. Subgroup analysis in subjects with dry skin. Mean ± SD. #; P < 0.1. n is the number of subjects.


Figure 6. Subjective feeling for the skin condition.
At 4 and 8 weeks, the subjects were asked, “How do you feel about your skin condition compared to before the intake?”. Statistical analysis was performed as the answers of “worse” as 1, “same” as 2, and “better” as 3. Subgroup analysis for ages under 50 years. n is the number of subjects. ***; P < 0.001.
Back

(2)The effect of CP on skin damage by ultraviolet rays.

There are two types of skin aging: intrinsic aging by the passage of time, and extrinsic aging (photoaging) by exposure to ultraviolet (UV) lights. Photoaging severely affects the facial skin exposed to sunlight. In 2009, we showed that the oral administration of CP alleviated skin damage caused by consecutive repeated exposure to UV lights in animal experiments (Reference 3). To elucidate the similar effects for humans, we conducted a randomized, double-blind, placebo-controlled clinical trial and examined whether daily intake of 5g of CP suppressed acute skin damage caused by a single exposure to UV lights for Japanese males (skin phototype II or III) aged 20-59 years (Reference 4).
Skin phototype II is burned (reddened) easily and not tanned easily. Skin phototype III is burned (reddened) and then tanned. These types are relatively sensitive to UV lights (Reference 5). In the animal experiments described above, UV light was irradiated continuously and repeatedly. However, consecutive repeated irradiation of UV lights to human skin would result in severe tanning. Then, a single irradiation of UV lights was conducted in this trial for ethical reasons. The dorsal skin was irradiated with UV light (the irradiation before intake). The values of a* (erythema index) were measured before and after the irradiation until the 15th day. Afterward, subjects took either 5 g of placebo (dextrin in this case) or CP (manufactured by Nippi) for 4 weeks. Then, the dorsal skin was irradiated singly with UV lights (the irradiation at 4-week intake). The values of a* were measured before and after the irradiation until the 15th day while continuing the intake (Figure 7).
After the irradiation before intake, the level of erythema was not different between the two groups (data not shown). However, after the irradiation at 4-week intake, it was significantly lower in the CP group than in the placebo group on day 4 (subgroup analysis: age > 30 years; Figure 8). Since erythema reflects increased blood flow (inflammatory response) associated with skin damage, the results indicate that CP intake suppressed the acute damage caused by UV-irradiation, suggesting its ability to alleviate photoaging caused by long-term sunlight exposure.



Figure 7. Schedule of the trial on UV-induced skin damage.
The dorsal skin was exposed to UV lights once (day 1 of the irradiation before intake). Before and after the irradiation, erythema (a* value) was measured on days 1, 4, 8, and 15. After that, subjects took either CP or a placebo for 4 weeks. Then, the dorsal skin was exposed to UV lights once (day 1 of the irradiation at 4-week intake). Before and after the exposure, erythema (a* value) was measured on days 1, 4, 8, and 15 while continuing intake of test food. Statistical analysis was performed between the groups.

Figure 8. Suppression of erythema by CP intake.
Although no significant differences between the groups were observed after the exposure before intake (data not shown), the level of erythema was significantly lower in the CP group than in the placebo group on day 4 after the exposure at 4-week intake. Subgroup analysis in subjects aged 30-59. Mean ± SEM. *; P < 0.05. n is the number of subjects.
Back

(3)The effect of CP on immune function.

Our bodies are maintained in constant health conditions by the nervous, endocrine, and immune systems (homeostasis). The immune system can be impaired by stress, poor nutrition, and aging. Infectious disease is the leading cause of death in the elderly, indicating that the immune system is compromised in the elderly. There are individual differences in the decline of immune function (Reference 6). CP is a safe food ingredient with a long food experience. If its intake ameliorates immune function, CP can improve the quality of life (QOL) of the elderly and the homeostasis of people with immune function impaired due to severe stress.
Therefore, we conducted a randomized, double-blind, placebo-controlled, clinical trial to evaluate immune function in Japanese males and females in their 30s to 50s who feel tired easily. They took 10 g of CP or placebo (dextrin) daily for 8 weeks (Reference 7). Immune function was evaluated using the method of Hirokawa et al.*2 (Reference 6). The number of immune cells (T cells, CD4+ T cells, CD8+ T cells, naive T cells, memory T cells, CD8+ CD28+ T cells, B cells, and NK cells) in peripheral blood was counted (Table 1). The values of seven parameters (T cell count, a ratio of CD4+/CD8+ T cell count, naive T cell count, a ratio of naive/memory T cell count, CD8+ CD28+ T cell count, B cell count, and NK cell count) were then scored according to the database of healthy individuals, respectively (1: low, 2: moderate, and 3: high). The sum of the seven scores is the scoring of immunological vigor (SIV), an overall indicator of an individual immune function (Figure 9). The SIV is classified into three immunological grades according to the database of healthy individuals, defined as I: critical zone, II: warning zone, III: observation zone, IV: safety zone, and V: sufficiently high *3 (Figure 9). Number of CD8+ CD28+ T cells is known to decrease with age. “T-lymphocyte age” was calculated by matching CD8+ CD28+ T cell count to a database of healthy individuals (Figure 10). Questionnaires were administered using the Likert scale to assess subjective feelings about physical conditions.

*2: As of April 2015, this evaluation method is used by more than 50 medical institutions in Japan to assess immune function.

*3: The grade I (SIV of 9 or less) indicates the possibility of having some disease (critical zone). Therefore, subjects were selected from immunological grade II (warning zone) or III (observation zone).

In the intra-group comparison before and after 8 weeks of the intervention, significant changes were observed in 3 parameters (CD8+ T cell count, naive/memory T cell ratio, and B cell count) in the placebo group, possibly due to seasonal variations, placebo effects, or the effect of dextrin as a placebo. On the other hand, the CP group showed significant increases in the SIV, T cell count, memory T cell count, CD8+CD28+ T cell count, and NK cell count, and significant decreases in T lymphocyte age and CD4+ CD8+ T cell ratio, in addition to these three measurements (Table 2). The inter-group comparison showed that the SIV was significantly higher (P = 0.030) in the CP group (16.2 ± 1.6) than in the placebo group (15.6 ± 1.8), indicating that immune function improved after daily intake of CP (Table 3). Furthermore, no inter-group differences in the immunological grade were between the two groups before and after 8 weeks of the intervention. However, the number of warning zone was lower, and the number of safety zone was higher in the CP group than in the placebo group after the intervention (Figure 11). Regarding subjective feelings of physical conditions, "diarrhea" and "lack of appetite" were improved in only the CP group. These results indicate that when people feel easily fatigued with a weak immune system, CP intake can ameliorate the immune system and improve subjective symptoms.
Figure 9. Methods of assessing immune function (1).
The following shows the method using the immunological score and grade.
[Scoring of Immunological Vigor (SIV)] The values of the seven parameters (colored cells) are compared with the database of healthy individuals and converted into a score (1: low, 2: medium, and 3: high), which are then summed up.
[Immunological Grade] The SIV is compared with the database of healthy individuals and classified into five levels: I: critical zone, II: warning zone, III: observation zone, IV: safety zone, and V: sufficiently high.
The score and grade are indicators of an individual overall immune status.


Figure 10. Methods of assessing immune function (2).
“T lymphocyte age” is calculated by matching CD8+CD28+T cell count, which decreases with age, to a database of healthy individuals.



Figure 11. Change in the immunological grade.
Before and after 8 weeks of intake, there was no inter-group difference in the immunological grade.
However, after the intake, the number of the warning zone was lower, and the number of the safety zone was higher in the CP group than in the placebo group.


Table 1. The immunological parameters
The parameters used to evaluate immunological function are below.


Table 2. Intra-group variation of the immunological parameters
Statistical analysis of the changes before and after intake in the CP group is shown. In addition to the three parameters that changed significantly in the two groups (CD8+ T cell count, naive/memory T cell ratio, and B cell count), the parameters changed significantly only in the CP group in colored cells. n=25/group, Mean ± SD.


Table 3. Inter-group comparison of the immunological parameters
Statistical analysis of the difference between the two groups is shown. The SIV was significantly higher in the CP group than in the placebo group. n=25/group, Mean ± SD.
Back

SUMMARY

The results of our clinical trials demonstrated that dietary CP was effective in improving physical function. The findings of our research indicate that dietary CP may possess a multitude of nutritional functions. We will continue further research that, contributes to human health.

References

1. Kuwaba K, Koyama Y, Koikeda T, Tsukada Y. Effects of Collagen Peptide Ingestion on Skin Properties―Placebo–controlled Double–blind Trial―. Jpn Pharmacol Ther 42, 995-1004 (2014) in Japanese
2. Koyama Y. Effect of collagen peptide ingestion on the skin. Food processing and ingredients 44 (7), 10-12 (2009) in Japanese
3. Tanaka M, Koyama Y, Nomura Y. Effects of collagen peptide ingestion on UVB-induced skin damage. Biosci Biotechnol Biochem 73, 930-932 (2009)
4. Koyama Y, Kuwaba K, Kondo S, Tsukada Y. Supplemental ingestion of collagen peptide suppresses ultraviolet-induced erythema –A randomized double-blind placebo-controlled study- Jpn Pharmacol Ther 42, 781-790 (2014)
5. Bleehen SS, Ebling FJG, Champion RH. Chapter 35 Disorders of skin colors. In; Champion RH, Burton JL, Ebling FJG (eds.) Textbook of Dermatology Volume 3, 5th edition. Oxford BLACKWELL SCIENTIFIC PUBLICATION, 1561-1622 (1998)
6. Hirokawa K, Utsuyama M. Proper Assessment and Restoration of Immunological Function. Biotherapy 23, 1-12 (2009) in Japanese
7. Koyama Y, Kuwaba K, Kusubata M, Hayashida O, Takara T, Tsukada Y. Supplemental ingestion of collagen peptide improves T-cell-related human immune status --Placebo-controlled double-blind study-- Jpn Pharmacol Ther 43, 51-56 (2015)